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a b s t r a c t
Hepatitis C virus (HCV) represents a global health concern affecting over 185 million people worldwide.
Chronic HCV infection causes liver ﬁbrosis and cirrhosis and is the leading indication for liver
transplantation. Recent advances in the ﬁeld of direct-acting antiviral drugs (DAAs) promise a cure for
HCV in over 90% of cases that will get access to these expensive treatments. Nevertheless, the lack of a
protective vaccine and likely emergence of drug-resistant viral variants call for further studies of HCV
biology. With chimpanzees being for a long time the only non-human in vivo model of HCV infection,
strong efforts were put into establishing in vitro experimental systems. The initial models only enabled
to study speciﬁc aspects of the HCV life cycle, such as viral replication with the subgenomic replicon and
entry using HCV pseudotyped particles (HCVpp). Subsequent development of protocols to grow
infectious HCV particles in cell-culture (HCVcc) ignited investigations on the full cycle of HCV infection
and the virus–host interactions required for virus propagation.
More recently, small animal models permissive to HCV were generated that allowed in vivo
testing of novel antiviral therapies as well as vaccine candidates. This review provides an overview of
the currently available in vitro and in vivo experimental systems to study HCV biology. Particular
emphasis is given to how these model systems furthered our understanding of virus–host interactions,
viral pathogenesis and immunological responses to HCV infection, as well as drug and vaccine
development.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
Hepatitis C virus (HCV) is a (þ)-sense, single-stranded RNA virus
of the Flaviviridae family that infects humans and chimpanzees via
direct blood contact (e.g. intravenous drug use or contaminated blood
supplies) and targets primarily hepatocytes. Current estimates indi-
cate that more than 185 million people (approximately 3% of the
world's population) have been infected with the virus (Mohd
Hanaﬁah et al., 2013). HCV stains are classiﬁed into 7 genotypes
based on phylogenetic and sequence analyses (430% divergence at
nucleotide level). Genotypes 1 and 3 are the most prevalent world-
wide, accounting together for 137.7 million cases, while genotypes
4 and 5 are mostly distributed in lower-income countries (Messina et
al., 2015). More than 70% of the individuals contracting HCV pro-
gresses on developing a chronic infection that often remains asymp-
tomatic for decades. This suggests that the virus has evolved
successful strategies to overcome antiviral cellular defences and co-
exist with its host. Ultimately, however, chronic HCV infection leads to
the development of liver ﬁbrosis, cirrhosis, hepatocellular carcinoma
(HCC), and end-stage liver disease.
For twenty years, HCV has been treated with interferon (IFN)-
based regimens that present important side effects and are ineffective
in at least 50% of cases (Manns et al., 2006). Exciting progress on the
HCV therapy front were made in 2011, when the ﬁrst direct-acting
antivirals (DAAs) received approval from the US Food and Drug
Administration. DAAs target the NS3/4A protease, the NS5A protein,
or the NS5B polymerase and when used in appropriate combinations
they achieve very high cure rates, with sustained virological responses
(SVR) above 90% of cases (Aghemo and De Francesco, 2013).
The recent successes stem from two decades of efforts in building
the necessary experimental systems that led to crucial breakthroughs
on various aspects of HCV infection. The unique species and tissue
tropism of HCV and the difﬁculty of generating suitable cell culture
and small animal models has posed a great challenge to investigate
HCV biology and the contribution of host responses to HCV persis-
tence or clearance. On the 25th anniversary of the discovery of HCV,
we can look back to assess the progress made and acknowledge that
much has been learned about this pathogen. We can now study all
the steps of its life cycle in vitro and in small animal models, dissect
the virus–host interactions that mediate infection, and can begin to
understand how the host contributes to establishment of chronicity,
and progression of HCV-mediated disease.
HCV represents a peculiar and puzzling example of a virion, in that
it circulates in the bloodstream of the infected individuals associated
with host lipoproteins in a complex structure called the lipoviral
particle (LVP) (Andre et al., 2002). HCV reaches its target organ, the
liver, by crossing the fenestrated endothelium and interacting initially
with attachment factors like heparan sulfate proteoglycans (HSPGs)
and receptors such as the tetraspanin CD81 on the basolateral side of
hepatocytes (Barth et al., 2003; Pileri et al., 1998). The interaction of
HCV virions with endogenous lipoproteins represents an efﬁcient
mode of entry into the liver cells of a new host. In fact, the list of HCV
receptors includes two lipoprotein receptors: the scavenger receptor
class B, type I (SR-BI)(Scarselli et al., 2002a) and the low-density
lipoprotein receptor (LDLR)(Agnello et al., 1999). The model of HCV
entry has become increasingly complicated with six novel entry
factors identiﬁed over the last eight years only: the tight junction
molecules claudin-1 (CLDN1) (Evans et al., 2007) and occludin (OCLN)
(Ploss et al., 2009), the epidermal growth factor receptor (EGFR) and
the ephrin type-A receptor 2 (EphA2) (Lupberger et al., 2011), the
cholesterol uptake molecule Niemann–Pick C1-like 1 (NPC1L1) (Sainz
et al., 2012) and the transferrin receptor 1 (TFR1) (Martin and
Uprichard, 2013). So far, direct proof of interaction with the virus
exists for CD81 and SR-BI only, which were identiﬁed as candidate
receptors precisely for their ability to bind the HCV envelope
glycoprotein, E2 (Pileri et al., 1998; Scarselli et al., 2002a). Because
of the spatial segregation of HCV receptors into different subcellular
domains, active transport towards the apical side is thought to occur,
bringing the virus in close proximity of additional entry factors, such
as CLDN1 and OCLN. EGFR-mediated signaling via Ras, as well as Rho
GTPase, have been proposed to induce lateral movement of CD81-
bound virions to the cell-cell contact sites where CD81 would then
engage CLDN1. HCV internalization then occurs by clathrin-
mediated endocytosis. Finally, delivery of the virus to Rab5a-
positive early endosomes should provide the acidic environment
necessary to induce fusion (Zeisel et al., 2013). Fusion of the viral
envelope with the endosome subsequently releases the viral capsid
into the cytoplasm where the viral RNA genome is immediately
translated to produce the HCV polyprotein. The concerted action of
host- and viral-encoded proteases leads to the production of ten
viral proteins. The ﬁrst three proteins are structural components of
the virion: Core, which forms the nucleocapsid, and the viral
envelope glycoproteins, E1 and E2. The non-structural (NS) proteins
include the ion channel p7, the auto-protease NS2, the protease/
helicase NS3/4A, NS4B, NS5A and the viral RNA-dependent RNA
polymerase NS5B. The replicase complexes assemble on the endo-
plasmatic reticulum (ER), forming invaginations of ER membranes
called the “membranous web”. It is within these nuclease-resistant
compartments that HCV RNA is transcribed. The resulting progeny
HCV RNA is then packaged into viral capsids, decorated with viral
glycoproteins and secreted from the cells via the secretory pathway.
Although the exact mechanism of LVP formation is not fully
elucidated, at some point during the maturation process, HCV
virions acquire endogenous lipids and a thick shell of host-derived
apolipoproteins coating the viral envelope that presumably aid both
release and entry of the virus. In fact, the secretion of nascent virions
from infected cells is tightly linked to the very-low density lipopro-
tein (VLDL) biosynthetic pathway, with the strongest evidence being
that apoE is essential for particle release (Bartenschlager et al., 2011).
In addition to infecting hepatocytes from the bloodstream, an
entry route that is termed “cell-free”, HCV particles can be directly
transmitted between neighboring cells, so called “cell-to-cell” spread.
The lateral movement of HCV without diffusion through the extra-
cellular environment could facilitate viral dissemination, especially
since two of its co-receptors, CLDN1 and OCLN, are recruited to the
intercellular interface. The extent to which cell-free versus cell-to-cell
transmission contribute to HCV persistence is unknown, but the
latter route provides potential advantages in terms of infection
efﬁciency and immune evasion and, as such, may be more relevant
for maintaining infection over the course of the years.
In this review, we highlight the main in vitro and in vivo
experimental systems that have enabled studies of HCV so far and
provide an outlook on further developments that can improve our
ability to understand and treat this virus.
In vitro systems
Since the discovery of HCV in 1989 (Choo et al., 1989), the lack of a
cell culture system for the production of infectious HCV virions
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represented a major obstacle to study this pathogen and to devise
strategies for prophylactic and therapeutic interventions. Historically,
patient-derived HCV isolates failed to initiate productive infection in
cell culture. In 1997, the development of HCV molecular clones that
were infectious in chimpanzees was an important initial break-
through, however these viral genomes did not produce viral particles
in cell culture (Kolykhalov et al., 1997; Yanagi et al., 1997). Soon after,
different surrogate systems were developed to dissect individual steps
of HCV life cycle. These include: the subgenomic replicon, the soluble
E2 protein (sE2) and the HCV pseudo particles (HCVpp) (Fig. 1).
The HCV subgenomic replicon system
In 1999, Lohmann et al. deﬁned the minimal set of HCV proteins
required to initiate and maintain HCV replication in human cells
(Lohmann et al., 1999). The HCV NS3/4A protease, NS4B, involved in
forming themembranous web harboring the replicase complex (Konan
et al., 2003), the NS5A protein as well as the RNA-dependent RNA
polymerase NS5B are indispensable for HCV replication (Fig. 1b). The
subgenomic replicon is based on a bicistronic RNA construct, which
drives an antibiotic resistance gene from the HCV internal ribosomal
entry site (IRES), while the HCV non-structural proteins (NS3-NS5B) are
expressed from an encephalomyocarditis virus (EMCV) IRES. Transfec-
tion of in vitro-transcribed RNA into Huh-7 cells followed by antibiotic
selection results in the production of cell lines stably replicating HCV at
low levels. No infectious particles are released in this system, however,
due to the lack of structural proteins. Several adaptive mutations are
selected in the replicative process, ultimately leading to the emer-
gence of variants with higher replicative ﬁtness (Abe et al., 2007;
Blight et al., 2000; Bukh et al., 2002; Ikeda et al., 2002; Krieger et al.,
2001; Liang et al., 2005; Lohmann et al., 2001; Maekawa et al., 2004;
Yi and Lemon, 2004). These mutations typically cluster in distinct
regions of the N-terminus of the NS3 helicase (Krieger et al., 2001;
Liefhebber et al., 2010), in NS4B (Welker et al., 2012) and in NS5A
(Krieger et al., 2001; Shimakami et al., 2004; Tong and Malcolm,
2006). Subgenomic replicons have been described for HCV geno-
types 1a (H77(Blight et al., 2003)), 1b (Con1 (Ikeda et al., 2002),
HCV-N (Ikeda et al., 2002), HCV-BK (Graziani and Paonessa, 2004),
HCV-J4 (Gates et al., 2004), 1B-2/HCV-O (Kato et al., 2003) and 1B-1/
M1LE (Kato et al., 2003)), 2a (JFH1 (Targett-Adams and McLauchlan,
2005)), 3 (S52 (Saeed et al., 2013, 2012)), 4 (ED43 (Peng et al., 2012;
Saeed et al., 2012)), 5a (Wose Kinge et al., 2014) and 6a (Yu et al.,
2014) (Table 1) and have greatly contributed to the development of
DAA currently licensed or in development. In addition to drug-
selectable subgenomic replicon systems, several reporter-encoding
versions have been described (King et al., 2002; Krieger et al., 2001),
greatly simplifying the evaluation of antiviral drug potency. To date,
the greatest advantage of the HCV subgenomic replicon over the
HCVcc system is its non-restrictive nature in terms of HCV geno-
types that can be studied.
Soluble E2 ectodomain (sE2)
The ﬁrst tool used to search for HCV receptors was a soluble form
of the HCV glycoprotein E2 (sE2), which is devoid of its transmem-
brane region, leading to secretion of the ectodomain (Fig. 1c).
Truncations are usually made at amino acid 661 (Michalak et al.,
1997). The ﬁrst two HCV entry receptors, the tetraspanin CD81 and
the scavenger receptor SR-BI, were identiﬁed in screenings based on
sE2 binding to human hepatoma cell lines (Pileri et al., 1998;
Scarselli et al., 2002b). Although it is not produced in complex with
E1, sE2 was shown to retain proper folding as indicated by its ability
Fig. 1. HCV lifecycle and surrogate models systems to study HCV biology. (a) Overview of the HCV life cycle. The virus interacts with target cells by binding to attachment
factors and receptors (1) that mediate its internalization through clathrin-mediated endocytosis (2). Fusion of the viral and cellular membranes, triggered by the low pH of
the endocytic compartment, leads to release of the positive-strand RNA genome (þ) into the cytoplasm (3). The HCV genome is translated by host ribosomes to generate a
polyprotein precursor that is processed by both host and viral proteases to give rise to 10 viral proteins (4). The non-structural (NS) proteins form a replication complex,
which produces multiple copies of the HCV RNA genome via a minus-strand replicative intermediate (5). Progeny RNA can either re-enter the lifecycle, to produce more HCV
proteins or be packaged into nucleocapsids (6). Budding of the nucleocapsid into the endoplasmic reticulum (ER) leads to the acquisition of the viral envelope as well as E1
and E2 glycoproteins. Along the secretory pathway, virions undergo maturation and associate with endogenous lipoproteins to form lipoviral particles (7), which are released
from the cell (8) or transmitted directly through tight junctions to infect neighboring cells by cell-to-cell spread (9). (b–d) Surrogate model systems to study individual steps
of HCV life cycle. (b) The HCV replicon encodes the selectable marker neomycin (neo) under control of the HCV IRES in the ﬁrst cistron and the HCV replicase proteins (NS3-
NS5B) under control of an heterologous IRES from EMCV in the second cistron, allowing for viral replication in hepatoma cells after HCV RNA delivery by electroporation.
Replication of HCV RNA leads to the concomitant production of the selectable marker and enables selection of cells harboring replicating subgenomic HCV RNA by G418
treatment. (c) Schematic representation of the soluble ectodomain of the HCV glycoprotein E2 (sE2). The hypervariable regions (HVR) 1, 2 and 3 are indicated. The numbers
correspond to the positions in the HCV polyprotein of the strain H77, genotype 1a. 3D structure of sE2 (courtesy of Prof J. Marcotrigiano and Dr M. Miller, Rutgers University).
(d) HCV pseudoparticles (HCVpp) consist of unmodiﬁed HCV envelope glycoproteins assembled onto retroviral core particles and are produced by co-transfection of 293 T
cells with expression vectors encoding (1) HCV E1/E2, (2) HIV Gag-Pol proteins and (3) a retroviral genome encoding a reporter gene such as luciferase or green ﬂuorescent
protein to allow quantitative measurement of HCV entry into target cells.
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to interact with CD81, to block HCVcc entry and to bind antibodies
from HCV infected patients (Whidby et al., 2009). Recently, the
structure of E2 ectodomain in complex to two different Fabs was
solved, revealing a globular shape with IgG-like folds and disordered
ﬂexible regions (Khan et al., 2014; Kong et al., 2013). Interestingly,
this core region of E2 does not contain an obvious fusion peptide,
nor does it undergo signiﬁcant conformational rearrangements upon
incubation at low pH, ruling out a direct involvement of E2 in the
fusion process. These ﬁndings represent exciting insights into the
mechanisms of HCV entry and will aid vaccine development.
HCV pseudo particles (HCVpp)
A major breakthrough for investigating the process of HCV entry
was the development of pseudoparticles (HCVpp), which consist of
defective retroviral particles expressing HCV envelope glycoproteins
on their surface (Bartosch et al., 2003; Hsu et al., 2003). HCVpp
are produced by co-transfecting 293T cells with three expression
plasmids encoding: (1) the HCV glycoproteins E1 and E2, (2) Gag–Pol
proteins of human immunodeﬁciency virus (HIV) or murine leukemia
virus (MLV) and (3) a retroviral genome containing a reporter gene
such as luciferase or GFP to allow quantitative measurement of HCV
entry into target cells (Fig. 1d). This system was instrumental to study
the role of E1 and E2 glycoproteins in HCV entry, to identify and
validate candidate HCV attachment factors and receptors and to shed
light on the mechanisms of virus internalization (Zeisel et al., 2013).
Furthermore, the generation of HCVpp expressing patient-derived
viral glycoprotein sequences enabled studies on the neutralizing
properties of E1/E2-speciﬁc antibodies and led to the identiﬁcation
of cross-neutralizing epitopes (Tarr et al., 2006). HCVpp offer an
opportunity for investigating the step of virus entry uncoupled from
downstream events, facilitating for instance studies in cells that are
not permissive to HCV replication. A caveat of this model is that it
does not recapitulate the association of HCV with circulating
lipoproteins. This is due to the fact that HCVpp are generated in a
kidney cell line, which does not synthesize lipoproteins, and that these
particles assemble similar to retroviruses. Nevertheless, the compar-
ison between HCVpp and HCVcc can provide insights into key aspects
of virion morphogenesis that impact on HCV entry and neutralization.
Model systems to study the complete HCV life cycle
Cell culture derived HCV (HCVcc)
HCV infection of cells with patient-derived isolates does not result
in productive infection. The reasons for that still remain obscure. So
far, the only exception is a genotype 2a HCV isolate from a Japanese
patient with fulminant HCV-associated hepatitis (JFH1), which is
able to initiate low-level infection in Huh-7 cells, paving the way
to studying the complete HCV life cycle in cell culture (Lindenbach
et al., 2005; Wakita et al., 2005; Zhong et al., 2005). The ability to
propagate HCV in vitro has greatly beneﬁtted our understanding of
HCV biology. For example, the HCVcc system led to the identiﬁca-
tion of novel entry factors, such as NPC1L1 (Sainz et al., 2012), EGFR
and EphA2 (Lupberger et al., 2011). This model system enabled for
the ﬁrst time studies of HCV assembly and egress (Hueging et al.,
2014; Mancone et al., 2011; Nag et al., 2012), the characterization
of biophysical and ultrastructural properties of the HCV virion
(Catanese et al., 2013b; Gastaminza et al., 2010; Merz et al., 2011;
Nielsen et al., 2006). Importantly, HCVcc was infectious in chim-
panzees and human liver-chimeric mice (Lindenbach et al., 2006),
facilitating the evaluation of vaccine candidates in vivo (de Jong
et al., 2014; Law et al., 2008; Prentoe et al., 2011) and the develop-
ment of genetically humanized mice (Dorner et al., 2013, 2011).
Combination of the original JFH1 NS3-NS5B region with the
C-NS2 region from another genotype 2a isolate (J6) resulted in intra-
genotypic chimeras with enhanced replicative ﬁtness (Lohmann
Table 1
Summary of subgenomic replicon and HCVcc systems for different HCV genotypes.
Strain Genotype Replicon HCVcc
H77 1a Blight et al. (2003), Grobler et al. (2003), Tscherne et al. (2006) Pietschmann et al. (2006)a, McMullan et al. (2007)a, Li et al. (2015)
H77c 1a Yi et al. (2004) Russell et al. (2009), Yi et al. (2007), Scheel et al. (2009)a, Yi et al. (2006)
HCV-1 1a Lanford et al. (2006) –
Con1 1b Lohmann et al. (1999), Blight et al. (2000), Guo et al. (2001),
Krieger et al. (2001), Lohmann et al. (2003)
Pietschmann et al. (2009)a, Gottwein et al. (2009)a, Kaul et al. (2007)a, Pietschmann
et al. (2006)a
HCV-N 1b Guo et al. (2001), Ikeda et al. (2002), Yi et al. (2002) –
HCV-
BK
1b Grobler et al. (2003) –
HCV-
J4
1b Maekawa et al. (2004) –
O 1b Abe et al. (2007), Ikeda et al. (2005), Kato et al. (2003) –
AH1 1b Mori et al. (2008) –
NC1 1b Date et al. (2012) Date et al. (2012)a
BHCV1 1b – Koutsoudakis et al. (2011)a
TNcc 1b – Li et al. (2012)
JFH1 2a Kato et al. (2003) Wakita et al. (2005), Zhong et al. (2005), Delagrange et al. (2007), Kang et al. (2009),
Zhong et al. (2006) Kaul et al. (2007), Russel et al. (2008),
J6/
JF-
H1,
Jc1
2a – Lindenbach et al. (2005)a, Pietschmann et al. (2006)a, Bungyoku et al. (2009)a
HCV-
J8
2b Saeed et al. (2012) Gottwein et al. (2007)a, Ramirez et al. (2014)
S52 3a – Gottwein et al. (2007)a, Gottwein et al. (2009)a
452 3a Saeed et al. (2012), Peng et al. (2012) Kaul et al. (2007)a, Pietschmann et al., (2006)a
ED43 4a Kinge et al. (2014) Scheel et al. (2008)a
SA1 5a – –
SA13 5a Yu et al. (2014) Gottwein et al. (2007)a, Jensen et al. (2008)a
HK6a 6a – Gottwein et al. (2007)a
QC69 7a Gottwein et al. (2007)a
a Chimeric constructs.
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et al., 2003). The resulting J6/JFH1 (Lindenbach et al., 2006)
(genotype breakpoint between NS2 and NS3) or Jc1 (Pietschmann
et al., 2006) (genotype breakpoint within NS2) were characterized
by enhanced virus replication, spread and particle production
(Fig. 2). In addition to various intergenotypic chimeras, HCVcc has
also been serially passaged to select for viral clones with enhanced
replication in hepatoma cells (Bungyoku et al., 2009; Catanese et al.,
2013a; Date et al., 2012; Liu et al., 2012). The resulting titer-
enhancing mutations are scattered throughout the HCV genome,
suggesting that various mutations can promote viral propagation
in vitro. Different mechanisms were identiﬁed to be responsible for
this effect, ranging from enhanced entry, replication, to particle
release and cell-to-cell spread
Several reporter genomes have been created, allowing conveni-
ent and dynamic measurements of viral replication using
luminescent or ﬂuorescent readouts. Reporter genes were either
fused to viral proteins (i.e. NS5A) (Gottwein et al., 2011a, 2011b) or
added as additional proteins (Andrus et al., 2011; Liu et al., 2012,
2014a; Chan et al., 2013; Horwitz et al., 2013), that are cleaved off
the viral polyprotein by the NS3/4A protease (i.e. by duplicating the
NS5A-B cleavage site) (Fig. 2). Since most DAAs have been devel-
oped using genotype 1 subgenomic replicon systems Bukh et al.
developed several intergenotypic chimeras by replacing the C-NS2
region (Gottwein et al., 2007, 2010, 2009; Russell et al., 2009; Scheel
et al., 2008; Jensen et al., 2008), the NS3/4A protease (Gottwein et
al., 2013, 2011b), NS5A (Scheel et al., 2012, 2011; Gottwein et al., 2013;
Galli et al., 2013; Li et al., 2014a) and/or NS5B (Herlihy et al., 2008) or
all but NS3/4a and NS5b (Li et al., 2014a) of the J6/JFH1 genotype 2a
backbone with other viral genotypes (1–7) to evaluate their potency
against other HCV genotypes. This usually impairs viral ﬁtness but
Fig. 2. Cell culture-derived HCV. (a) Structure of the HCV genome. Functions of the individual viral proteins are indicated. (b) HCVcc reporter viruses encode ﬂuorescent
(e.g. Ypet, RFP) or luminescent proteins (Gluc) to facilitate detection of HCV-infected cells. (c) Intergenotypic chimeras facilitating the study of individual HCV proteins
(i.e. structural proteins C-NS2, NS3/4A, NS5A, NS5B or NS3/4A and NS5B) of different genotypes on the backbone of the replication-competent genotype 2a HCVcc system.
Core to NS2 and NS5A intergenotypic chimeras are available for genotypes 1–7 whereas all other intergenotypic chimeras are restricted to individual genotypes.
All intergenotypic viral genomes require in vitro selection and acquire adaptive mutations that increase viral replication.
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compensatory mutations can be selected, restoring wild-type replica-
tive ﬁtness. Recently, the ﬁrst full-length genotype 1 and 2 HCV
genomes were developed that recapitulate the complete virus life
cycle in vitro (Li et al., 2012, 2014b; Ramirez et al., 2014).
Cell systems permissive to HCV infection
As expected for a human hepatotropic virus, HCV replicates
primarily in human hepatocytes. Nevertheless, the development of
cell systems to study HCV infection in the laboratory proved to be
a big challenge, taking almost a decade from the discovery of the
virus. This is likely a reﬂection of the fact that the cell models
utilized do not fully mimic the liver physiology but also that HCV,
being a chronic virus, may have not evolved to replicate in its
target cells to very high levels.
To date, the cells most permissive to HCV replication
in vitro are a human hepatoma cell line, Huh-7, and its
derivatives (Fig. 3a). These cells vary signiﬁcantly in their
ability to support HCV replication, although the molecular
mechanisms accounting for such phenomenon remain incomple-
tely understood. This heterogeneity was exploited to select for cell
clones that sustained higher replication levels. Among these, the
most widely used are Huh-7.5 cells (Blight et al., 2002) thatcarry a
loss-of-function missense mutation in Retinoic Acid-Inducible Gene
I (RIG-I), resulting in defective antiviral signaling (Sumpter et al.,
2005), and enablesigniﬁcantly higher production of infectious
particles and robust spread in cell culture. A limitation of this
system lies in the lack of cell polarity, which does not allow
mimicking the compartmentalization of HCV receptors or the
directionality of the secretory systems observed in polarized hepa-
tocytes. As a result, certain aspects of HCV entry, assembly and
interaction with lipoproteins or cell-to-cell spread may not be
reproduced in Huh-7.5 cells (Steinmann and Pietschmann, 2013).
In contrast, HepG2 cells are known to polarize in culture. Although
normally refractory to HCV infection due to lack of CD81 expression,
these cells can be rendered fully permissive to HCV upon ectopic
expression of human CD81 and miR-122, to promote viral entry and
replication, respectively (Flint et al., 2006; Mee et al., 2009; Narbus
et al., 2011). The liver-speciﬁc microRNA miR-122, which binds to
the 5'UTR of HCV and is thought to stabilize viral RNA (Jopling et al.,
2006) furthermore is able to render non-hepatic cells permissive to
HCV replication (Kambara et al., 2012; Vogt et al., 2013). Other
approaches to study HCV in polarized human hepatoma cells
included treatment with 1% dimethyl sulfoxide (Sainz and Chisari,
2006) and growth in 3D using matrigel or rotating wall vessel
(Molina-Jimenez et al., 2012; Sainz et al., 2009).
While highly permissive hepatoma cell lines represented the
obvious choice for initial studies of HCV biology, this culture system
does not fully recapitulate all aspects of HCV replication in the liver
and discrepancies may derive from the biased nature of this model.
For instance, we are missing key information on the contribution
that the host plays in the outcome of infection, be it viral clearance
or persistence. As such, the ultimate goal in terms of cell system for
HCV is to achieve reproducible and sustained infection in more
physiologic cultures of primary human hepatocytes (PHH), which
represent the natural host cell for HCV, from genetically diverse
donors. However, a series of limitations have made this a signiﬁcant
challenge, including poor availability of these cells, high costs, loss
of differentiation and short survival in cell culture. Even today, a
major challenge remains, which limits HCV studies in physiological
cell culture systems – the poor permissiveness of PHH to HCV
infection.
Human fetal liver cells (HFLC) were shown to be long-lived and to
support HCV replication to higher levels compared with cultured
adult human hepatocytes (Iacovacci et al., 1997; Lazaro et al., 2007).
Although signiﬁcantly less permissive than hepatoma cells,
HFLC showed variable infection frequency depending on the donor
cell preparations (Fig. 3a). In most cases, however, little to no viral
spread was observed in these culturesunless interferon responses
were antagonized by expressing paramyxovirus (PMV) V proteins
Fig. 3. Cell systems permissive to HCV infection. (a) Comparative analysis of cellular systems available for the study of HCV infection and their prperties. *A recent report
(Yang et al., 2014) described the ﬁrst human hepatoma cell line naturally permissive to HBV and HCV patient isolates. (b) The RFP-NLS-IPS cell based HCV reporter system
and its application to identify HCV infection in living cells. The NS3/4A protease cleavage of IPS1 from the mitochondrial membrane is exploited to create a reporter by
constructing a fusion protein between the IPS1 transmembrane domain, a nuclear localization signal (NLS) and a red ﬂuorescence protein (RFP). This allows sensitive
detection of infection in living cells even with low viral replication levels and can be exploited in ﬂuorescence microscopy or image-based ﬂow cytometry.
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or by treating with a TBK-1 inhibitor that suppresses several
pathogen-associated pattern recognition receptors, including
RIG-I (Andrus et al., 2011; Catanese et al., 2013b).
In an effort to prolong the survival and differentiation state of
PHH, co-culture models have been developed, based on the
observation that feeder cells were fundamental to PHH viability
and biological functions. Micropatterned co-cultures (MPCCs)
consist of islands of PHH seeded on large collagen micropatterns
surrounded by ﬁbroblasts. PHH in this culture system are polar-
ized and permissive to HCV, albeit the efﬁciency of infection
remains very low due to innate antiviral immune responses
(Ploss et al., 2010) (Fig. 3a). A combination of MPCCs with the
strategies outlined above to inhibit IFN-mediated antiviral
responses would improve both cell survival/physiology and sus-
ceptibility to HCV infection, thus facilitating studies in PHH.
Given the low replication levels and infection frequency in PHH
cultures, conventional virological assays established for hepatoma
cells, based on detection of viral antigens, were often not sensitive
enough to ascertain HCV infection. Although the quantiﬁcation of
viral genomes by RT-qPCR represents a very sensitive technique, it
suffers from high background due to contamination by viral inocula
or input RNA used for transfection. To overcome this hurdle, cell
reporter systems were developed that exploit the cleavage of the
NS3/4A protease to monitor HCV infection. In one case, the recogni-
tion sequence of the viral protease was fused in frame with a
secreted alkaline phosphatase (SEAP), enabling rapid and sensitive
quantiﬁcation of HCV infection and viral replication by measuring
SEAP activity in the cell culture medium (Iro et al., 2009). The other
version was based on the expression of a red ﬂuorescent protein
(RFP) and a nuclear localization signal (NLS) fused to residues 462–
540 of human interferon-β promoter stimulator protein 1 (IPS-1,
also called MAVS, Cardif, VISA), a mitochondrial protein targeted by
HCV (Jones et al., 2010). This region of IPS-1 encompasses the NS3/
4a protease cleavage site, therefore upon HCV infection, cleavage of
IPS-1 results in relocalization of the ﬂuorescent protein from the
mitochondria to the nucleus (Fig. 3b). Importantly, cells expressing
RFP-NLS-IPS can be used to track HCV infection in real time and at a
single cell level. This cellular reporter system was successfully
exploited for monitoring HCV cell-to-cell spread in hepatoma cells
(Catanese et al., 2013a) and PHH (Andrus et al., 2011), for ex vivo
studies of hepatocytes explanted frommouse livers (Fig. 3b) (Dorner
et al., 2013) and for laser capture microdissection approaches that
enabled transcriptional proﬁling of infected and uninfected PHH
cells (Sheahan et al., 2014).
Recent studies using hepatocyte-like cells derived from
induced pluripotent stem cells (iPSC) and human embryonic stem
cells (hESC) have shown that these cells can be infected with
HCVcc, offering an opportunity to study the contribution of host
genetics to HCV pathogenesis (Roelandt et al., 2012; Schwartz
et al., 2012; Wu et al., 2012)
In addition to hepatocytes, HCV RNA and proteins have been
detected at low levels in various other tissues, including lymphatic
system, brain and gut (Fletcher et al., 2012; Franks, 2012; Ito et al.,
2010; Liu et al., 2014b; Pawlowski et al., 2014). However, it remains
to be determined whether these truly represent extrahepatic
reservoirs that contribute to HCV persistence and extrahepatic
manifestations of chronic HCV infection (Cacoub et al., 2014). In
this respect, testing sensitivity of these systems to antiviral
compounds is key to distinguishing between HCV detection and
productive infection (Dustin and Rice, 2011).
In vivo models
Chimpanzee
Chimpanzees (Pan troglodytes) are naturally susceptible to HCV
infection and their use in HCV research has greatly advanced our
understanding of HCV biology. With over 98% genetic identity to
humans it is not surprising that HCV can utilize chimpanzee host
factors with comparable efﬁciency to human orthologs. Ranging
from early studies aiding in the identiﬁcation of HCV as the cause of
non-A non-B hepatitis (Weiner et al., 1990), the creation of an
infectious cDNA clone for HCV (Kolykhalov et al., 1997; Yanagi et al.,
1997; Yanagi et al., 1998) to the study of immune responses (Bigger
et al., 2001; Grakoui et al., 2003; Major et al., 2002; Mizukoshi et al.,
2002; Nascimbeni et al., 2003) and the evaluation of vaccine
candidates (Elmowalid et al., 2007; Forns et al., 2000; Fuller et al.,
2013; Meunier et al., 2011; Mikkelsen et al., 2011) the chimpanzee
was the most important in vivo model for HCV until 2013 when
chimpanzee research was banned in most countries due to ethical
concerns .
Tupaia
Besides chimpanzees, the treeshrew (Tupaia belangeri) was
shown to be susceptible to HCV infection (Xie et al., 1998). HCV
can utilize the tupaia orthologs of CD81, SR-BI, CLDN1 and OCLN
for gaining entry into tupaia hepatocytes. (Tong et al., 2011; Jia et
al., 2008; Xu et al., 2007; Barth et al., 2005) Infection leads to
transient HCV viraemia, which results in mild hepatitis during the
acute phase of infection (Xu et al., 2007). While encouraging, the
inability to recapitulate the chronic phase of HCV, the unavail-
ability of tools to study host responses as well as the difﬁculties in
breeding treeshrews in captivity limits their widespread use in
HCV research.
Genetically humanized mouse models
Mice are naturally resistant to HCV infection. Both virus entry and
replication are limited in murine cells. The second extracellular loops
of murine CD81 and OCLN have been identiﬁed as responsible for
restricting species tropism (Ploss et al., 2009). Mice expressing
human CD81 and OCLN, either via adenoviral gene delivery or by
transgenic expression, were shown to support HCV entry (Dorner
et al., 2011) making this model suitable to evaluate vaccine candi-
dates (Giang et al., 2012), neutralizing antibodies and cellular path-
ways important for virus entry (Fig. 4a). However, there is no
intracellular accumulation of viral RNA, indicating that viral RNA
replication is insufﬁciently recapitulated in murine cells (Dorner et
al., 2011). While the HCV protease is able to impair IFN signaling in
murine cells by cleaving IPS-1 (Vogt et al., 2013), additional pathways
may be responsible for inhibiting viral replication. Studies in murine
embryonic ﬁbroblasts have demonstrated that PKR- (Chang et al.,
2006) and IRF3-mediated immune responses (Lin et al., 2010) are the
main roadblock for HCV replication in murine cells. Combining
expression of human HCV entry factors with blunting of the mouse
innate immune responses (i.e. by using STAT1/ mice) was recently
shown to enable the recapitulation of the entire HCV life cycle, albeit
at low levels (Dorner et al., 2013)(Fig. 4b). In addition to delayed B
and T cell responses to HCV infection, liver inﬁltration of IFN-
producing NK cells coincided with decline of HCV replication.
A recent report compared different murine strains and described
striking differences in the ability of these models to maintain chronic
HCV infection (Chen et al., 2014). These data conﬁrm that the host
genetic background plays an important role in HCV infection.
Additionally, the presence of a fully developed immune system in
Imprinting Control Region (ICR) mice expressing human CD81 and
OCLN was associated with reduced levels of pre-albumin, hepatic
inﬂammation, leukocyte inﬁltration and ﬁbrosis development, sug-
gesting that innate immune activation is an essential driver of
immune-mediated HCV pathogenesis (Chen et al., 2014).
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Human liver chimeric mouse models
Direct humanization of the murine liver via xenotransplantation
offers an attractive model system for studying HCV interactions with
PHH in vivo. A common feature of all recipient strains is the require-
ment for extensive immunosuppression in order to facilitate human
graft maintenance(Fig. 4c). This is usually accomplished by using SCID/
Bg, Rag2 /IL2γRnull or NOD.Rag2 /IL2γRnull-based recipients, which
lack B cell, T cell as well as NK cell responses(Boermans et al., 1992; Le-
Barillec et al., 2005; Pearson et al., 2008). The liver is usually a quiescent
organ and proliferation of hepatocytes requires regenerative signals. In
human liver-chimeric mouse models, induction of liver injury to the
murine hepatocytes is commonly exploited for the delivery of pro-
liferative cues to human hepatocytes. Four models for the induction of
murine liver injury have been described. The initial and most widely
used model is based on transgenic overexpression of the urokinase
Plasminogen activator (uPA) in the liver of mice (Dandri et al., 2001;
Mercer et al., 2001; Rhim et al., 1995). Homozygous animals are
characterized by progressive liver injury and, upon intrasplenic injec-
tion of primary human hepatocytes will engraft to high levels. More
recent models have, in addition to the induction of liver injury added
the inducibility of liver insults to increase viability of recipient animals.
Among those, the fumaryl acetoacetate hydrolase (Fah)-deﬁcient strain
is most widely used(Azuma et al., 2007). Knock-out of the Fah gene,
which is responsible for metabolizing fumarylacetoacetate to acetoa-
cetate and fumarate results in accumulation of succinylacetate
and succinylacetone, which are toxic metabolites and induce liver
and renal damage. Supplementing these mice with 2-[2-nitro-4-
(triﬂuoromethyl)benzoyl]cyclohexane-1,3-dione (NTBC) inhibits an
upstream component in the tyrosine breakdown pathway, thus
protecting the animals from accumulation of toxic metabolites.
Other modes of inducible liver injury include expression of HSV
thymidine kinase (TK) (Hasegawa et al., 2011) and expression of a
fusion protein of the FK506 binding protein (FKBP) and caspase 8
(AFC8) (Washburn et al., 2011). Liver injury is induced in these
models by providing either an FKBP dimerizer to activate caspase
8 signaling or gancyclovir to activate the HSV thymidine kinase. The
advantage of using inducible liver injury models over uPA-
expressing mice is that the murine liver injury is reversible, thus
enabling longer life spans of reconstituted animals by cycling liver
injury. Reconstitution levels with human hepatocytes can be con-
veniently monitored using human-speciﬁc serum albumin Elisa
assays and studies revealed that 1 mg/mL of human albumin, which
is the minimum level for infection studies with HCV correlates to
10% of the liver being engrafted with human hepatocytes (Kawahara
et al., 2010). Strikingly, not only HCVcc can be used to infect human
liver-chimeric mice but also patient isolates of different genotypes
have successfully be used to launch infection (Mercer et al., 2001).
Even though HCV infection can be maintained for extensive periods
of time there are no reports of pathogenesis (i.e. ﬁbrosis, cirrhosis or
HCC) induced by HCV. Nevertheless, human liver-chimeric mice
have signiﬁcantly contributed to a better understanding of HCV
biology, ranging from the evaluation of HCV neutralizing (Akazawa
Fig. 4. HCV small-animal models. (a) Immunocompetent Rosa26Fluc luciferase reporter mice are rendered susceptible to HCV entry by adenoviral or transgenic expression of
the human orthologs of HCV receptors (CD81, OCLN, SR-BI and CLDN1). Infection with a Cre recombinase-encoding HCV genome triggers Cre/loxP-based excision of a
transcriptional stop cassette, activating luciferase expression, which is quantiﬁed by in vivo bioluminescence imaging. (b) Genetically humanized mice recapitulating all steps
of the HCV life cycle are based on expression of human HCV receptors in STAT1-deﬁcient animals. This facilitates persistent HCV infection, which can be detected for up to 90
days. (c) Human liver-chimeric mice are based on the ability of human hepatocytes to proliferate and repopulate a murine liver with genetically encoded liver injury. The
immunodeﬁcient background enables repopulation of the liver with up to 90% human hepatocytes, which in turn renders these mice permissive to patient-derived HCV.
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et al., 2013; Broering et al., 2009; de Jong et al., 2014; Faﬁ-Kremer et
al., 2010; Law et al., 2008; Meuleman et al., 2011) or receptor-
blocking (Ji et al., 2014; Meuleman et al., 2008) (Lacek et al., 2012;
Vercauteren et al., 2014) antibodies, the validation of the role of
EGFR, EphA2 (Lupberger et al., 2011) and NPC1L1(Sainz et al., 2012)
in HCV entry as well as the study of drug candidates targeting
various aspects of the HCV life cycle (Bhat et al., 2012; Gebert et al.,
2014; Gu et al., 2013; Jopling et al., 2006; Ray et al., 2013;
Vanwolleghem et al., 2007; Watanabe et al., 2013; Yang et al., 2010).
Recently, models harboring both a human liver and a human
immune system have been reported (Bility et al., 2014, 2012;
Washburn et al., 2011; Wilson et al., 2014). While the maintenance
of human hepatocytes is sufﬁciently achieved using mildly immu-
nodeﬁcient strains, engraftment and maintenance of a human
immune system following human hematopoietic stem cell injection
is only efﬁcient in mice on the NOD background. Both, AFC8 mice
and Fah-deﬁcient NOD.Rag2/IL2gRnull (FRGN) mice were shown
to engraft successfully with human liver and immune system
components, facilitating the study of human immune responses to
hepatotropic infectious diseases. AFC8 mice reconstituted with
human liver and immune system have been shown to develop liver
ﬁbrosis in response to HCV infection even though detection of liver
engraftment in this model requires qPCR ampliﬁcation of albumin
rather than measuring human serum albumin levels. Despite the
challenges in maintenance, engraftment and the not fully functional
immune system these models clearly constitute the most advanced
model to study HCV in its natural host environment.
Conclusions and future perspectives
The range of available model systems to study HCV has mas-
sively increased since the construction of the ﬁrst infectious cDNA
clone. An advantage of some of the early in vitro systems was
that they provided the opportunity to selectively study individual
aspects of the HCV life cycle. With the development of the HCVcc
system, the initial ﬁndings could be integrated into a more complex
model, advancing our understanding of virus assembly, release and
cell-to-cell spread. Several inter-genotypic chimeras have been
created, allowing, in combination with animal models, evaluation
of HCV antiviral agents and vaccine candidates. However, there is
still urgent need for in vitro systems permissive to patient-derived
HCV isolates. A recent report shows promising ﬁrst steps towards
this goal (Yang et al., 2014). Moreover, protocols to differentiate iPSC
and hESC cells into hepatocyte-like cells and to maintain PHH in
physiological systems will offer the opportunity to unveil novel
virus–host interactions as well as to understand the contribution of
the host to disease progression. With the introduction of highly
effective genome editing tools, it now becomes feasible to identify
important host factors using the same genetic background in a
virtually inexhaustible source of iPSC-derived hepatocytes.
Another challenge we face is that most HCV research relies on
two dimensional cell cultures with poor polarization, while cell
polarity is a crucial aspect of HCV entry into hepatocytes and is
also likely to impact virus release and spread. Furthermore, the
complexity of the liver is poorly recapitulated so far. In fact, none
of the available experimental systems utilizes non-parenchymal
cells (i.e. Kupffer cells, stellate cells), leaving their role in HCV
disease progression entirely unexplored.
Major advances were made in the ability to study HCV in vivo,
ranging from the identiﬁcation of the species tropism-deﬁning
HCV receptors CD81 and OCLN to the importance of innate
immunity in controlling HCV replication. This in turn led to the
development of immunocompetent models facilitating the study
of vaccine candidates, the ability to delineate important pathways
required for productive infection and the ability to evaluate drug
candidates. Recent advances furthermore include the generation
of a pigtail macaque (Macaca nemestrina) model permissive to HCV
infection (Date et al., 2012). Nevertheless, improvements to these
models can still be made. For instance, HCV infection can only be
established in these models with high titer inocula.
Human liver-chimeric mice on the other hand are permissive to
patient-derived HCV, thus allowing the study of relevant viral
genotypes. The recent combination of human liver-chimeric mice
with human immune system mice enabled to recapitulate for the
ﬁrst time the entire HCV life cycle in human hepatocytes in the
presence of a human immune system. However, improvements to
this model are still needed prior to its applicability to study
vaccine candidates. B cell responses, which are required for anti-
body production, are only rudimentary in human immune system-
containing mice as well as myeloid cells, which are underrepre-
sented in most model systems. Furthermore, there is no evidence
for the presence of non-parenchymal cells other than hepatocytes
in human liver-chimeric mice, urging the need for the develop-
ment of models harboring human Kupffer cells, stellate cells or
liver sinusoidal endothelial cells, thus facilitating the dissection of
their impact on HCV pathogenesis.
In conclusion, the in vitro and in vivo model systems developed
for HCV so far have greatly contributed to our understanding of the
intricate viral life cycle, host-pathogen interactions, as well as
immunology. Despite the utilization of these models for the devel-
opment of DAAs promising over 90% SVR, signiﬁcant challenges still
remain. The inability to determine the optimal treatment regimen on
a personalized medicine level, using patient-derived HCV will likely
lead to the emergence of resistance mutations. Even though patients
with successful SVR are considered cured these drug-resistant viral
strains might be propagated through de novo infections, thus making
DAAs less effective. Additionally, even if all infected individuals
obtained treatment, at anticipated SVR rates of 90%, over 17 million
patients will likely fail therapy, even with multi-DAA combinations.
Combining these numbers with the large number of people who is
not aware of having contracted HCV or cannot afford DAA treatment
mandates further research into developing therapeutic as well as
prophylactic strategies applicable to all people infected.
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